Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/469)
  • Patent number: 11166911
    Abstract: The present invention provides a parenteral dosage form consisting essentially of a solution filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to 3.9 and further wherein the dosage form is sterilized by subjecting the filled container to autoclaving.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 9, 2021
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Samarth Kumar, Soni Maheshkumar Parasmal, Milan Mohanbhai Vasoya, Prashant Kane, Subhas Balaram Bhowmick, Rajamannar Thennati
  • Patent number: 11141400
    Abstract: One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least ½ hour prior to administration, no food at least 1 hour prior to administration, no food at least 1½ hours prior to administration, no food at least 2 hours prior to administration, no food at least 2½ hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: October 12, 2021
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
  • Patent number: 11129877
    Abstract: A composition in the form of an injectable aqueous solution, for which the pH is comprised from 6.0 to 8.0, includes at least: a) amylin, an amylin receptor agonist or an amylin analogue; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid being constituted of glutamic or aspartic units and said hydrophobic radicals Hy chosen according to formula X as defined below: c) characterized in that the composition does not include basal insulin for which the isoelectric point IP is comprised from 5.8 to 8.5. The composition also includes a prandial insulin.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: September 28, 2021
    Assignee: ADOCIA
    Inventors: You-Ping Chan, Alexandre Geissler, Romain Noel, Richard Charvet, Nicolas Laurent
  • Patent number: 11033526
    Abstract: Citalopram or escitalopram, pharmaceutically acceptable salts or derivatives thereof for use in the treatment of neurodegenerative diseases The disclosure subject matter is related to the use of citalopram or escitalopram, pharmaceutically acceptable salts or derivatives thereof, in the treatment of neurodegenerative diseases that are positively influenced by the decrease of protein misfolding and/or aggregation, in particular by oral administration.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: June 15, 2021
    Assignee: UNIVERSIDADE DO MINHO
    Inventors: Patricia Espinheira De Sá Maciel, Andreia Cristiana Teixeira De Castro, Ana Luísa De Jales Monteiro De Sousa, Ana Sofia Teixeira Esteves, Nuno Jorge Carvalho Sousa
  • Patent number: 11021454
    Abstract: The present invention relates to a type of aryl benzofuran amidated derivatives, the medical use thereof, and the preparation method; said derivatives have antioxidation activity, and xanthine oxidase inhibitory activity, and can be used for antioxidation and for preparing compositions, drugs and health products and treating gout and hyperuricemia.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: June 1, 2021
    Assignee: CHINA PHARMACEUTICAL UNIVERSITY
    Inventor: Jun Chen
  • Patent number: 11000501
    Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of neurological diseases and mental diseases, the composition containing syringaresinol. The syringaresinol according to the present invention has an effect of reducing excitatory synaptic transmission in a central nervous system and an effect of suppressing epilepsy and activity of animals. This suppressive effect of the excitatory synaptic transmission may be effectively used for the prevention and treatment of all neurological diseases and mental diseases resulting from synapse dysfunction and synpatic excitatory-inhibitory transmission imbalance.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: May 11, 2021
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Myoung Hwan Kim, Young Seon Cho, Woo Seok Song
  • Patent number: 10980770
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: February 16, 2020
    Date of Patent: April 20, 2021
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Patent number: 10774027
    Abstract: The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin derivatives, such as treprostinil.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: September 15, 2020
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, David A. Walsh
  • Patent number: 10653665
    Abstract: Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 19, 2020
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Christian Lavedan, Mihael H. Polymeropoulos
  • Patent number: 10654820
    Abstract: Crystal forms I and II of tasimelteon. Crystal form I: an X-ray powder diffraction spectrum using CuK? radiation and represented by a 2? angle has diffraction peaks at least at 7.2°±0.2°, 7.9°±0.2°, 10.6°±0.2°, 14.4°±0.2°, 15.9°±0.2°, 17.3°±0.2°, 21.0°±0.2°, 23.2°±0.2°, and 24.4°±0.2°. Crystal form II: an X-ray powder diffraction spectrum using CuK? radiation and represented by a 2? angle has diffraction peaks at least at 6.8°±0.2°, 12.1°±0.2°, 12.5°±0.2°, 13.1°±0.2°, 13.6°±0.2°, 13.8°±0.2°, 15.8°±0.2°, 17.0°±0.2°, 18.4°±0.2°, 20.8°±0.2°, 24.2°±0.2°, and 24.4°±0.2°. Crystal forms I and II of tasimelteon have advantages of excellent physicochemical property, good stability and solubility, and simple operation for preparation.
    Type: Grant
    Filed: February 19, 2017
    Date of Patent: May 19, 2020
    Assignee: ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD.
    Inventors: Jianrong Zhu, Chunyong Peng, Hongban Zhong, Xiurong Hu
  • Patent number: 10556256
    Abstract: A novel technique is provided for preserving a liquid pharmaceutical preparation safely and stably. The nano-bubble water of the present invention, which is produced in the presence of a surfactant, a hydrophilic resin and/or an electrolyte and contains not less than 2.0×108 bubbles/mL of nano-bubbles, shows a superior antibacterial action, and can be used as a base of a liquid pharmaceutical preparation showing safe and stable preservation property.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: February 11, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Naoyuki Murata, Jiichi Arai
  • Patent number: 10508076
    Abstract: Provided is a method for resolution of formula 4-[4-dimethylamino-1-(4-fluorophenyl)-1-hydroxylbutyl]-3-hydroxy-methyl benzonitrile as an enantiomer thereof, comprising the following steps: a salt of (S)-4-[4-dimethylamino-1-(4-fluorophenyl)-1-hydroxylbutyl]-3-hydroxymethyl benzonitrile with a resolving agent D-(+)di-p-toluoyl tartaric acid was crystallized in a resolving solvent; the method is characterized in that the resolving solvent is an ether solvent. Also provided is a new crystal form of the resolved intermediate.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: December 17, 2019
    Assignee: Zhejiang huahai Pharmaceuticals Co., Ltd.
    Inventors: Zunjun Liang, Siqi Hu, Caihua Peng, Wenfeng Huang, Qifeng Lu, Guoliang Tu
  • Patent number: 10508093
    Abstract: The inventive subject matter provides compounds, compositions and methods for lowering serum acid (sUA) for the treatment of gout, and having reduced liver toxicity, associated with CYP2C9 metabolic pathway.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: December 17, 2019
    Assignee: ARTHROSI THERAPEUTICS, INC.
    Inventors: Shunqi Yan, Li-Tain Yeh, Robert Orr
  • Patent number: 10420742
    Abstract: Disclosed herein are compositions and methods for treating or preventing certain cancers in a subject. In certain embodiments such compositions and methods generally relate to the use of G-coupled protein receptor 40 (GPR40) agonists to inhibit the growth or induce apoptosis of certain cancer cells. The compositions and related methods disclosed herein may be used to treat subjects affected by cancers, such as melanoma, medullary thyroid carcinoma, malignant peripheral nerve sheath tumors and neuroblastoma, and to reduce the incidence of metastases in such affected subjects.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: September 24, 2019
    Assignee: The Children's Medical Center Corporation
    Inventors: Mark Puder, Deepika Nehra, Brian Kalish
  • Patent number: 10239854
    Abstract: The inventive subject matter provides compounds, compositions and methods for lowering serum acid (sUA) for the treatment of gout, and having reduced liver toxicity, associated with CYP2C9 metabolic pathway.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: March 26, 2019
    Assignee: ARTHROSI THERAPEUTICS, INC.
    Inventors: Shunqi Yan, Li-Tain Yeh, Robert Orr
  • Patent number: 10213464
    Abstract: The present invention provides a novel method for enhancing engraftment of haematopoetic stem cells by an ex-vivo pretreatment comprising the steps of obtaining a sample containing haematopoetic stem cells and admixing a prostacyclin analog to obtain a mixture, incubating said mixture for a period of time sufficient to stimulate G alphas-signalling in said cells and optionally and isolating said stimulated cells. Further, a composition comprising a prostacyclin analog for use in the treatment of individuals undergoing haematopoetic stem cell transplantation is provided.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: February 26, 2019
    Assignee: SCIPHARM SARL
    Inventors: Michael Freissmuth, Eva-Maria Zebedin-Brandl, Christian Bergmayr, Filza Hussain
  • Patent number: 10196342
    Abstract: The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin derivatives, such as treprostinil.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: February 5, 2019
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, David A. Walsh
  • Patent number: 10189783
    Abstract: The present invention relates to a an imide compound according to anyone of formulas Ia, Ib, Ic, or Ie wherein R1 is H or a C1-C20 optionally substituted hydrocarbon group; both R2 and R5 are a COOH group or one of R2 and R5 is a COOH group while the other substituent is H, methyl or ethyl group; R3 and R4 are independently H, or C1-C20 optionally substituted hydrocarbon group; R6 is H or a methyl group; R7 and R8 are independently H, methyl or ethyl.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: January 29, 2019
    Assignee: DSM IP ASSETS B.V.
    Inventors: Cornelis Eme Koning, Paulus Franciscus Anna Buijsen, Adrianus Jozephus Hendricus Lansbergen, Alwin Papegaaij, Douglas Hayden
  • Patent number: 10179119
    Abstract: Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
    Type: Grant
    Filed: August 29, 2015
    Date of Patent: January 15, 2019
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Christian Lavedan, Mihael H. Polymeropoulos
  • Patent number: 10017487
    Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (I) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification].
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: July 10, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Keiko Kakegawa, Zenichi Ikeda, Minoru Sasaki, Fumiaki Kikuchi, Yoichi Nishikawa
  • Patent number: 9920036
    Abstract: Compounds of Formula (I), including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: (I).
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: March 20, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, John F. Kadow
  • Patent number: 9913823
    Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: March 13, 2018
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Byung Gyu Kim, Hyun Woo Jeong, Su Kyung Kim, Si Young Cho, Chan Woong Park, Dae Bang Seo, Wan Gi Kim, Sang Jun Lee
  • Patent number: 9895340
    Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: February 20, 2018
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards
  • Patent number: 9782383
    Abstract: It is already known that 1-(benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof exhibits an excellent effect as an antidepressant, a psychotropic drug, an antiparkinsonian drug, and an anti-Alzheimer's disease drug. However, it has not been known at all that the compound is effective for the prevention or therapy of attention-deficit/hyperactivity disorder (ADHD). The present invention has newly found that 1-(benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof is effective for the prevention or therapy of ADHD, and has been accomplished.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: October 10, 2017
    Assignee: FUJIMOTO CO., LTD.
    Inventors: Hiroko Togashi, Sachiko Hiraide, Fumio Yoneda, Kazue Takahata
  • Patent number: 9745319
    Abstract: Irreversible inhibitors of K-Ras, H-Ras or N-ras protein comprising a G12C mutation are provided. Also disclosed are methods to regulate the activity of K-Ras, H-Ras or N-ras protein comprising G12C mutation and methods to disease mediated by K-Ras, H-Ras or N-ras G12C.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 29, 2017
    Assignee: ARAXES PHARMA LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Jun Feng
  • Patent number: 9700540
    Abstract: The invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis, formulations and associations comprising dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: July 11, 2017
    Assignee: SANOFI
    Inventors: Stephane Beilles, Sandra Chambonnet, Jean-Pierre Collaveri
  • Patent number: 9642828
    Abstract: The present invention relates to a stable, sterile, ready to administer parenteral dosage form of amiodarone or its pharmaceutically acceptable salt. Particularly, the present invention provides a stable, sterile, ready to administer parenteral dosage form of amiodarone comprising an aqueous solution comprising amiodarone or its pharmaceutically acceptable salt, an acid, and a polyol, wherein the pH of the solution is in the range of about 2.0 to 4.0, wherein the solution is filled in a plastic container and wherein the solution is free of a solubilizer.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: May 9, 2017
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Amar Kishorbhai Rana, Shantaram Pawar, Prashant Kane, Subhas Balaram Bhowmick, Maheshkumar Parasmal Soni, Milan Mohanbhai Vasoya, Samarth Kumar
  • Patent number: 9624189
    Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 18, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards
  • Patent number: 9604952
    Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: March 28, 2017
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan, Ji-Hye Kang
  • Patent number: 9549913
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: January 24, 2017
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
  • Patent number: 9517232
    Abstract: The invention is directed to the use of a compound of formula I, as defined herein, to a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing a compound of formula I, and to a combination of a compound of formula I with a pharmacologically effective cholinesterase inhibitor to treat a mammal, including a human, for a disorder or condition selected from the list including Alzheimer's disease, Huntington's disease, Parkinson's disease, non-Alzheimer's dementias and ALS.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: December 13, 2016
    Assignee: Medi Synergics, LLC
    Inventors: Dennis Michael Godek, Harry Ralph Howard
  • Patent number: 9492426
    Abstract: In some embodiments, the present invention provides methods of treating a tumor in a subject. In some embodiments, the methods may include a step of administering to the subject a therapeutic composition that comprises: (a) mycophenolic acid, an analog thereof, or a derivative thereof; and (b) at least one anti-neoplastic agent. In some embodiments, the antineoplastic agent may include at least one of 5-fluouracil (5-FU), paclitaxel, oxaliplatin, doxorubicin, etoposide, irinotecan, bleomycin, imiquimod, 13-cis-retinoic acid, and combinations thereof. In some embodiments, the relative concentrations of the mycophenolic acid, the analog thereof, or the derivative thereof, and the at least one anti-neoplastic agent correspond to their respective IC50 values.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: November 15, 2016
    Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Robert Y. Tsai, Tao Lin
  • Patent number: 9474733
    Abstract: The object of the invention is the use of compounds comprising one or more free sulphlydryl or amino groups for preparing a pharmaceutical composition for locally binding acetaldehyde in saliva, the stomach or the large intestine, and pharmaceutical compositions comprising the said compounds.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: October 25, 2016
    Assignee: BIOHIT OYJ
    Inventors: Mikko Salaspuro, Martti Marvola
  • Patent number: 9468627
    Abstract: The present invention concerns the treatment of serotonergic dysregulation disorders and/or augmentation of serotonin levels in the brain by add-on treatments to serotonin enhancers, and slow-release formulations of 5-hydroxytryptophan (5-HTP) therefor.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: October 18, 2016
    Assignee: Duke University
    Inventors: Jacob P. R. Jacobsen, Marc G. Caron
  • Patent number: 9434738
    Abstract: Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: September 6, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, John F. Kadow
  • Patent number: 9408816
    Abstract: Provided herein are methods for using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity, methods for monitoring the decrease of cellular DNA repair activity using at least one biomarker, methods of treating cancer by using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity in combination therapy, methods of combination therapy where at least one histone deacetylase inhibitor interferes with a DNA repairing mechanism involving RAD51, methods for predicting a induction time period between a first administration of at least one histone deacetylase inhibitor and a second administration of at least one other therapeutic treatment, and pharmaceutical compositions for combination therapy.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: August 9, 2016
    Assignee: Pharmacyclics LLC
    Inventors: Shanthi Adimoolam, Joseph J. Buggy, Darren Magda, Richard Miller
  • Patent number: 9346842
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: May 24, 2016
    Assignee: Bionomics Limited
    Inventors: Jason Hugh Chaplin, Gurmit Singh Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis
  • Patent number: 9278947
    Abstract: Serotonin reuptake inhibitor compounds which are designed to exert serotonin uptake inhibitory activity in the peripheral system while being devoid of CNS activity, and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with peripheral serotonin levels and/or activity, and/or platelet aggregation.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: March 8, 2016
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Moshe Rehavi, David Gurwitz
  • Patent number: 9155790
    Abstract: Methods for modulating eye damage associated with a disease or disorder, and/or damage incident to trauma including but not limited to trauma associated with ocular surgery are provided. In some embodiments, the methods include administering an effective amount of a modulator of a migration inhibitory factor (MIF) polypeptide biological activity to a subject. Also provided are methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of an ocular disease, and methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of scarring and/or other consequence of wound healing incident to ocular surgery, as well as modulating the survival, function, and/or differentiation of engrafted cells that can be employed as part of tissue engineering procedures to correct structural, functional, and/or cellular defects of the eye.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: October 13, 2015
    Assignee: University of Lousiville Research Foundation, Inc.
    Inventors: Tongalp H. Tezel, Henry J. Kaplan, Robert A. Mitchell, John O. Trent
  • Patent number: 9107900
    Abstract: Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: August 18, 2015
    Assignee: SANOFI
    Inventors: Davide Radzik, Martin Van Eickels, Nacera Hamdani, Christophe Gaudin
  • Patent number: 9102608
    Abstract: Provided is a simple, safe, and industrially practical method for producing a pentafluorosulfanylbenzoic acid.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: August 11, 2015
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Norimichi Saito, Junichi Chika
  • Patent number: 9066880
    Abstract: This invention relates to cosmetic and pharmaceutical preparations comprising (i) a diastereomer or a mixture of two or more diastereomers of the compound of formula (I) or (ii) a salt of a diastereomer or of a mixture of two or more diastereomers of the compound of formula (I) or (iii) a mixture of two or more salts of a diastereomer or of a mixture of two or more diastereomers of the compound of formula (I), a diastereomer, salt or a mixture as defined above as a drug for topical application and/or for the treatment of lipoatrophy; the non-therapeutic use of a diastereomer, salt or a mixture as defined above for the prevention, treatment or reduction of skin aging, especially skin wrinkles; the use of a diastereomer, salt or a mixture as defined above for the production of an orally administered non-pharmaceutical preparation.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: June 30, 2015
    Assignee: SYMRISE AG
    Inventors: Imke Meyer, Oskar Koch, Jean Krutmann
  • Patent number: 9060995
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: June 23, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Publication number: 20150148353
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:
    Type: Application
    Filed: June 28, 2013
    Publication date: May 28, 2015
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventor: John S. Kovach
  • Publication number: 20150148359
    Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 28, 2015
    Inventors: Uri Ben-David, Nissim Benvenisty, Payal Arora, Qing-Fen Gan, Ralph J. Garippa
  • Publication number: 20150148408
    Abstract: Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 28, 2015
    Inventors: Mohamed Naquib Attala, Philippe Diaz
  • Patent number: 9040066
    Abstract: This invention is based upon the discovery that a mixture of ethyl lactate and isoamyl lactate can be used to improve the penetration of active ingredients in skin care formulations through the outer layers of the stratum corneum and viable epidermis and into the dermis layer of the skin structure. The present invention more specifically discloses a method of rejuvenating skin comprising topically applying a topical formulation to the skin, wherein the topical formulation is comprised of ascorbic acid, an amino acid selected from the group consisting of phenylalanine and tyrosine, a non-toxic zinc salt, carnosic acid, ?-tocopherol, 0.01 weight percent to 20 weight percent of a mixture of ethyl lactate and isoamyl lactate, wherein the weight ratio of the ethyl lactate to the isoamyl lactate is within the range of 1:10 to 20:1, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: May 26, 2015
    Assignee: Ad Lunam Labs, Inc.
    Inventors: William H. Beeson, Alvin T. Rockhill
  • Patent number: 9040553
    Abstract: The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: May 26, 2015
    Assignee: CELL VIABLE CORPORATION
    Inventors: Iraj Lalezari, Jill Fabricant
  • Publication number: 20150141380
    Abstract: A method of treating a subject at risk of or suspected of having Fragile X syndrome or autism spectrum disorder associated with abnormalities of ERK includes administering to the subject a therapeutically effective amount of at least one ERK inhibiting compound that prevents abnormalities in neuronal connectivity, a prodrug thereof that is metabolisable to form the compound, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2011
    Publication date: May 21, 2015
    Applicant: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Mark A. Smith, Michael Snape
  • Publication number: 20150141465
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventors: Calvin W. YEE, Zhe Li